<p>Baseline characteristics, treatment efficacy, and serious adverse events in natalizumab-treated MS patients without prior treatment</p>

Helmut Butzkueven; Shibeshih Belachew; Ludwig Kappos; Fabio Pellegrini; Maria Trojano; Heinz Wiendl; Annie Zhang; Ryan Arnold

Home Browse Baseline characteristics, treatment efficacy, and serious adverse...

Poster

NOT PEER REVIEWED

Download

metrics

VIEWS

363

downloads

SEE MORE DETAILS

CITE

How to cite this poster:

Butzkueven H, Belachew S, Kappos L et al. Baseline characteristics, treatment efficacy, and serious adverse events in natalizumab-treated MS patients without prior treatment. F1000Posters 2012, 3:862 (poster)

Baseline characteristics, treatment efficacy, and serious adverse events in natalizumab-treated MS patients without prior treatment

Helmut Butzkueven¹, Shibeshih Belachew, Ludwig Kappos, Fabio Pellegrini, Maria Trojano, Heinz Wiendl, Annie Zhang, Ryan Arnold

Published 31 Jul 2012

Author Affiliations

¹ Department of Medicine and Melbourne Brain Centre, Royal Melbourne Hospital, Australia

Copyright © 2012 Butzkueven H et al. This is an open access work distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Metrics
363 Views
18 Downloads

DOWNLOAD 397.52 KB

CITE

Published 31 Jul 2012

Baseline characteristics, treatment efficacy, and serious adverse events in natalizumab-treated MS patients without prior treatment
[version 1; not peer reviewed]

Helmut Butzkueven¹, Shibeshih Belachew, Ludwig Kappos, Fabio Pellegrini, Maria Trojano, Heinz Wiendl, Annie Zhang, Ryan Arnold

Author Affiliations

¹ Department of Medicine and Melbourne Brain Centre, Royal Melbourne Hospital, Australia

Presented at

22nd Meeting of the European Neurological Society 2012

Abstract

Competing Interests

Corresponding author Helmut Butzkueven is on the scientific advisory boards and receives travel support of Biogen Idec, Merck Serono, Novartis, sanofi-aventis. He has also been involved in the steering committees for trials conducted by Biogen Idec, Merck Serono, Novartis and received research support from Biogen Idec, Merck Serono, Novartis, as the honorary chair of the MSBase Foundation. Helmut is on the editorial board of Multiple Sclerosis International Federation and Multiple Sclerosis and Related Disorders, and is the current recipient of National Health and Medical Research Council (NHMRC)Career Development Award, NHMRC Project Grants, NHMRC Centre of Excellence Award, Australian Research Council Linkage Grant, and a National MS Society (USA) Project Grant.

Coauthor Shibeshih Belachew is a consultant for Bayer Schering, Biogen Idec, Merck Serono. Shibeshih also receives educational funding from Biogen Idec, Merck Serono, Novartis, sanofi-aventis, Teva.

Coauthor Ludwig Kappos has received payments as the principal investigator, member, or chair of planning and steering committees or advisory boards in corporate-sponsored clinical trials that have been sponsored by Actelion, Bayer HealthCare, Bayer Schering, Biogen Idec, BioMarin, CLC Behring, Elan, GeNeuro, Genmab, Genmark, GlaxoSmithKline, Lilly, Merck Serono, Novartis, Novonordisk, Peptimmune, sanofi-aventis, Santhera, Roche, Teva, UCB, and Wyeth. There has also been payments exclusively used for the funding of research at Ludwig's department with support coming from; Actelion, Bayer HealthCare, Bayer Schering, Biogen Idec, BioMarin, CLC Behring, Elan, Genmab, GeNeuro, Genmark, GlaxoSmithKline, Lilly, Merck Serono, Novartis, Novo Nordisk, Peptimmune, sanofi-aventis, Santhera, Roche, Teva, UCB, Wyeth. Ludwig has also received grants from the Swiss MS Society, the Swiss National Research Foundation, the European Union, the Gianni Rubatto, Novartis and Roche Research Foundations.

Coauthor Fabio Pellegrini receives honoraria and is also a consultant for Biogen Idec.

Coauthor Marie Trojano receives research support from Merck Serono and is a consultant/speaker honoraria for Bayer Schering, Biogen Idec, and sanofi-aventis.

Coauthor Heinz Wiendl receives honoraria from Bayer, Biogen Idec/Elan, Medac, Merck Serono, Novo Nordisk, sanofi-aventis, Schering, Teva. He also receives research support from Bayer, Biogen Idec/Elan, Merck Serono, Novo Nordisk, Medac, sanofi-aventis, Schering, Teva and is a consultant for BayerVital/Schering, Biogen Idec, Medac, Merck Serono, Novartis, Novo Nordisk, sanofi-aventis, Teva.

Coauthors Annie Zhang and Ryan Arnold are paid employees of Biogen Idec.

Comments

0 Comments

All commenters must hold a formal affiliation as per our Policies. The information that you give us will be displayed next to your comment.

User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.

I accept the User Comment Terms and Conditions

Affiliation

Please enter your institution.

Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered.

Please select your country/region.

Competing Interests

Please disclose any competing interests that might be construed to influence your judgment of the content's validity or importance.

Use of this website is subject to the F1000 Research Limited (F1000) General Terms and Conditions.

Submission of user comments to this website is subject to additional Terms and Conditions. By clicking "I accept the User Comment Terms and Conditions" before you submit your first comment, you agree to be bound by these conditions every time you submit a comment.

Terms relating to user comments

This Agreement shall begin on the date hereof.
Certain parts of this website offer the opportunity for users to post and exchange opinions, information, material and data ('Comments') in areas of the website. F1000 does not screen, edit, publish or review Comments prior to their appearance on the website and Comments do not reflect the views or opinions of F1000, its agents or affiliates. Comments reflect the view and opinion of the person who posts such view or opinion. To the extent permitted by applicable laws F1000 shall not be responsible or liable for the Comments or for any loss cost, liability, damages or expenses caused and or suffered as a result of any use of and/or posting of and/or appearance of the Comments on this website.
F1000 reserves the right to monitor all Comments and to remove any Comments which it considers in its absolute discretion to be inappropriate, offensive or otherwise in breach of these Terms and Conditions.
You warrant and represent that:
1. You are entitled to post the Comments on the website and have all necessary licenses and consents to do so;
2. the Comments do not infringe any intellectual property right, including without limitation copyright, patent or trademark, or other proprietary right of any third party;
3. the Comments do not contain any defamatory, libelous, offensive, indecent or otherwise unlawful material or material which is an invasion of privacy
4. the Comments do not contain any contaminating or destructive features or devices such as viruses, time bombs or coding designed to interrupt, destroy or limit the functionality of this website or any of this website's user's computer equipment or software; and
5. the Comments will not be used to solicit or promote business or custom or present commercial activities or unlawful activity.
You hereby grant to F1000 a non-exclusive royalty-free license to use, reproduce, edit and authorize others to use, reproduce and edit any of your Comments in any and all forms, formats or media.
You hereby agree to indemnify and keep indemnified F1000, its affiliates, contractors and agents from and against any and all losses (including without limitation direct, indirect and consequential loss), costs, claims, damages or expenses of whatever nature and howsoever caused arising directly or indirectly from any breach of these Terms and Conditions or arising from the Comments posted on this website or content contained in any email sent using the facilities provided by the website by you including without limitation as a result of any infringement of any intellectual property or other proprietary rights, libel, defamation, obscenity or the Comments being otherwise unlawful.

Competing Interests

Please disclose any competing interests that might be construed to influence your judgment of the content's validity or importance.

Baseline characteristics, treatment efficacy, and serious adverse events in natalizumab-treated MS patients without prior treatment

Baseline characteristics, treatment efficacy, and serious adverse events in natalizumab-treated MS patients without prior treatment [version 1; not peer reviewed]

Terms relating to user comments

Baseline characteristics, treatment efficacy, and serious adverse events in natalizumab-treated MS patients without prior treatment
[version 1; not peer reviewed]